1. COVAX, the global vaccine pillar, is financially supported by the EU and its Member States under a Team Europe approach with EUR 3 billion.

In addition, Team Europe has shared so far about 300 million doses via COVAX, which is now transferring them to low and middle-income countries. In addition, Team Europe has also delivered over 45 million vaccines through bilateral donations. The Union Civil Protection Mechanism plays an important role through operational and logistical support in these bilateral donations.

In addition to donation targets by the EU Member States, the Commission will add a donation of 200 million doses by mid-2022. This brings the Team Europe target to 700 million doses by mid-2022.

2. The Team Europe Initiative for manufacturing vaccines, medicines and health technologies aims to support the African Union’s goal to produce 60% of Africa’s needs locally by 2040. Financial instruments are being designed to support the enabling environment and bankable investment projects to boost local capacity along the value chain. Country readiness, mobilisation of domestic resources, favourable business, trade environment and engagement of the pharmaceutical industry are key factors for investment. No specific conditionality or criteria are being applied.

3. As for the intellectual property waiver proposed in the World Trade Organization, the Commission is actively engaged in the process to find a way forward in the discussion on the role of intellectual property in enhancing access to affordable COVID-19 vaccines and therapeutics.

---